Mobic’s blockbuster potential follows COX-2 bad news

Share this article:
Abbott Laboratories reported sales of its NSAID Mobic jumped 176 percent following Merck's withdrawal of Vioxx from the market and news that studies have linked Celebrex and Bextra to heart risk.
Sales of Mobic nearly tripled to $258 million in the fourth quarter of 2004, exceeding most Wall Street estimates by at least $100 million.
Mobic, originally estimated to be a moderate seller, is now expected to achieve blockbuster status with a potential for $1 billion in sales, Abbott said detailing its fourth quarter earnings this week.
The news also is a boon for Germany's Boehringer Ingelheim, which licensed Mobic to Abbott in a co-marketing agreement. The terms of that agreement are slated to change in April, with more Mobic profits going to Boehringer. 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.